An International Comparison of the Efficacy, Cost and Myelotoxicity of First-Line Therapy for Advanced Follicular Non-Hodgkin Lymphoma

Hematological Oncology - United Kingdom
doi 10.1002/hon.2439_121
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Recent Advances in the First-Line Treatment of Follicular Non-Hodgkin Lymphoma

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2019English

Bendamustine-Based Therapy as First-Line Treatment for Non-Hodgkin Lymphoma

Medical Oncology
MedicineCancer ResearchOncologyHematology
2014English

Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2014English

Efficacy and Safety of Icotinib as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2016English

Choosing the Appropriate Salvage Therapy for B-Cell Non-Hodgkin Lymphoma

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2018English

PET-CT-adapted Therapy for Advanced Hodgkin Lymphoma: A Systematic Review of the Literature

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Management of Patients With Follicular Lymphoma Treated First Line With Obinutuzumab

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2019English

Consolidation Therapy for Follicular Lymphoma

European Oncology and Haematology
OncologyHematology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy